Skip to Main Content

INFORMATION FOR

Michael DiGiovanna, MD, PhD

Professor of Internal Medicine (Medical Oncology); Chair, Breast Cancer Tumor Board, Yale Cancer Center; Curriculum Director, Office of Education; Thread Leader, Pharmacology, Office of Education; Master Course Co-Leader, Office of Education

Contact Information

Michael DiGiovanna, MD, PhD

Patient Care Location

Mailing Address

  • Medical Oncology

    PO Box 208032, 300 George Street

    New Haven, CT 06520-8032

    United States

Appointments

Biography

Dr. DiGiovanna is a native of Long Island, NY, who graduated from Cornell University in 1984 with a B.A. and a double major in the fields of biochemistry and music. He attended Yale University from 1984 through 1990 where he was earned the MD and PhD degrees, with his PhD in Pharmacology. He continued his post-graduate training at Yale, performing internship and residency in Internal Medicine, a research post-doctoral fellowship, and a clinical fellowship in Medical Oncology. He is currently an attending physician in Medical Oncology and Professor of Medicine (Oncology) and Pharmacology at Yale University. His clinical specialty is breast cancer and he conducts both clinical and laboratory-based research. His translational laboratory research focuses on signal transduction in breast cancer. He also has had many leadership roles in education at the Yale School of Medicine, including current roles as Co-Director of the Pre-Clerkship Curriculum, Pharmacology Thread Leader, and Co-Leader of the Genes & Development Master Course. Learn more about Dr. DiGiovanna>>

Education & Training

  • Fellow
    Yale School of Medicine (1997)
  • Postdoctoral Fellow
    Yale University (1997)
  • Resident
    Yale University School of Medicine (1994)
  • PhD
    Yale University (1990)
  • MD
    Yale University (1990)
  • BA
    Cornell University, Biology (Biochemistry), Music (1984)

Activities

  • Current chemo-treatments and protocols for breast cancer management
    New York, NY, United States 2019
    Current chemo-treatments and protocols for breast cancer management
  • Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an Oncotype Dx Recurrence Score (≤25)
    San Antonio, TX, United States 2019
    Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an Oncotype Dx Recurrence Score (≤25)
  • Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer
    San Antonio, TX, United States 2019
    Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer
  • Adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
    San Antonio, TX, United States 2019
    Adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
  • Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
    San Antonio, TX, United States 2018
    San Antonio Breast Cancer Symposium
  • Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)
    Chicago, IL, United States 2018
    American Society of Clinical Oncology, Annual Meeting
  • An Evening Symposium on Breast Cancer – Incorporating Emerging Practice Options for HER2 and ER+ Breast Cancer
    Tampa, FL, United States 2017
    An Evening Symposium on Breast Cancer – Incorporating Emerging Practice Options for HER2 and ER+ Breast Cancer
  • Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fouorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer
    Chicago, IL, United States 2017
    American Society of Clinical Oncology, Annual Meeting
  • Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (dd AC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A phase I/II trial
    Chicago, IL, United States 2017
    American Society of Clinical Oncology, Annual Meeting
  • Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?
    Westwood, KS, United States 2017
    Southwestern Surgical Congress, Annual Meeting
  • A novel approach to the medical student hematology curriculum
    San Diego, CA, United States 2016
    American Society of Hematology, Annual Meeting
  • Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study
    Chicago, IL, United States 2016
    American Society of Clinical Oncology, Annual Meeting
  • Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast Cancer Endocrine Therapy Adherence (BETA) Pilot Study
    San Antonio, TX, United States 2015
    San Antonio Breast Cancer Symposium
  • Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH)
    San Francisco, CA, United States 2015
    American Society of Clinical Oncology Breast Cancer Symposium
  • A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25)
    Chicago, IL, United States 2015
    American Society of Clinical Oncology, Annual Meeting
  • Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy
    Chicago, IL, United States 2015
    American Society of Clinical Oncology, Annual Meeting
  • Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools
    Chicago, IL, United States 2015
    American Society of Clinical Oncology, Annual Meeting
  • Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing
    Philadelphia, PA, United States 2015
    American Association for Cancer Research, Annual Meeting
  • Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors
    Chicago, IL, United States 2014
    American Society of Clinical Oncology, Annual Meeting
  • Training medical students and faculty to have constructive feedback discussions about courses
    New Haven, CT, United States 2014
    Northeastern Group on [Medical] Educational Affairs, Spring Annual Rretreat
  • Predictors of Use of Adjuvant Chemotherapy and Overall Survival Outcomes in Elderly Breast Cancer Patients
    Phoenix, AZ, United States 2014
    Society of Surgical Oncology Cancer Symposium
  • Characterization of the relationship between pathologic complete response from neoadjuvant treatment and survival measures in breast cancer subtypes: Implications for study design
    San Antonio, TX, United States 2013
    San Antonio Breast Cancer Symposium
  • Patterns of the use of primary systemic therapy in the United States
    San Antonio, TX, United States 2013
    San Antonio Breast Cancer Symposium
  • Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience
    San Antonio, TX, United States 2013
    San Antonio Breast Cancer Symposium
  • Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab therapy
    San Antonio, TX, United States 2013
    San Antonio Breast Cancer Symposium
  • The impact of survivorship care plans on knowledge among breast cancer survivors
    San Francisco, CA, United States 2013
    American Society of Clinical Oncology Breast Cancer Symposium
  • Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer
    Chicago, IL, United States 2013
    American Society of Clinical Oncology, Annual Meeting
  • Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study
    Chicago, IL, United States 2013
    American Society of Clinical Oncology, Annual Meeting
  • Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer
    Chicago, IL, United States 2013
    American Society of Clinical Oncology, Annual Meeting
  • Neoadjuvant weekly nap-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) + B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): a BrUOG study
    Chicago, IL, United States 2012
    American Society of Clinical Oncology, Annual Meeting
  • A phase I study of biweekly capecitabine and the histone deacetylase inhibitors (HDACi) vorinostat in advanced breast cancer (BC)
    Chicago, IL, United States 2011
    American Society of Clinical Oncology, Annual Meeting
  • Exploring a Therapeutic Role for IGF1R Inhibitors in Triple-Negative Breast Cancer
    San Antonio, TX, United States 2010
    San Antonio Breast Cancer Symposium
  • Trastuzumab (H) and Rapamycin (R) for treatment of HER-2 overexpressing metastatic breast cancer (BC) with prior disease progression on H based therapy: Safety and pharmacodynamic (PD) results
    San Antonio, TX, United States 2010
    San Antonio Breast Cancer Symposium
  • Evaluation of the mechanism of action of histone deacetylase inhibitors (HDACi) in the treatment of breast cancer (BC)
    Hollywood, FL, United States 2010
    ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer
  • Self-Management and Transitions in Palliative Care
    Quebec City, QC, Canada 2010
    18th International Congress on Palliative Care
  • Therapeutic Targeting of the Interactions Between Hormone and Growth Factor Receptor Signaling
    Troy, NY, United States 2010
    New Frontiers in Breast Cancer Research and Prevention
  • A phase Ι study of the mTOR inhibitor sirolimus (Rapamycin, R) in combination with nanoparticle albumin-bound paclitaxel (nab-P)
    Chicago, IL, United States 2010
    American Society of Clinical Oncology Annual Meeting
  • Blocking Cross-Talk Between ER and Growth Factor Pathways
    New York, NY, United States 2009
    Physicians’ Education Resource, Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant
  • What is breast cancer?
    West Haven, CT, United States 2009
    "Hope, Not Fear", Fourth Annual Breast Cancer Community Forum
  • Association between HER2/neu overexpression and calcifications in breast cancer
    Orlando, FL, United States 2009
    American Society of Clinical Oncology, Annual Meeting
  • Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology
    Orlando, FL, United States 2009
    American Society of Clinical Oncology, Annual Meeting
  • Insulin-like Growth Factor Receptor: Role in Breast Cancer
    Riyadh, Riyadh Province, Saudi Arabia 2008
    First Saudi Oncology Society International Breast Cancer Conference
  • Breast cancer
    Riyadh, Riyadh Province, Saudi Arabia 2008
    Medical Files
  • What is breast cancer?
    West Haven, CT, United States 2008
    "Hope, Not Fear", Third Annual Breast Cancer Community Forum
  • Neoadjuvant chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter
    Chicago, IL, United States 2008
    Society of Surgical Oncology Annual Cancer Symposium
  • Breast sentinel lymph node dissection (SLND) prior to preoperative chemotherapy
    Colorado Springs, CO, United States 2007
    Western Surgical Association Annual Meeting
  • Metastatic breast cancer
    North Haven, CT, United States 2007
    CTV Television Program
  • Pre-clinical studies of combination targeted therapies in breast cancer
    New Brunswick, NJ, United States 2007
    Cancer Center Grand Rounds
  • Chemotherapy and Hormonal Therapy Advances in Breast Cancer
    Stamford, CT, United States 2006
    Physicians’ Education Resource, Emerging Trends in Oncology: Updates from 2006 AACR and ASCO Meetings
  • Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC)
    Atlanta, GA, United States 2006
    American Society of Clinical Oncology, Annual Meeting
  • Combinations of drugs that block HER2, ER and IGF1R
    Hartford, CT, United States 2006
    Susan G. Komen Breast Cancer Foundation, “Breast Cancer: Survive and Conquer” Symposium
  • Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells
    Washington, DC, United States 2006
    American Association for Cancer Research, Annual Meeting
  • Herceptin as Adjuvant Therapy: A Dramatic Leap Forward in Improving the Cure Rate of Breast Cancer
    New Haven, CT, United States 2005
    Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium
  • Targeting the HER2-ER cross-talk in breast cancer
    Sunnybrook, AB, Canada 2004
    Sunnybrook Regional Cancer Centre Grand Rounds
  • Comparison of HER-2 and topoisomerase II amplification with outcome after cyclophosphamide, doxorubicin and 5 FU-based chemotherapy for Stage II breast cancer (CALGB 8541/150013)
    New Orleans, LA, United States 2004
    American Society of Clinical Oncology, Annual Meeting
  • Synergistic interactions between all-trans retinoic acid, Herceptin, and tamoxifen in BT-474 human breast cancer cells
    Orlando, FL, United States 2004
    American Association for Cancer Research, Annual Meeting
  • Targeting HER2 and ER in breast cancer
    Key Biscayne, FL, United States 2003
    American Cancer Society – Harry and Elsa Jiler-American Cancer Society Professors Meeting
  • Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer (MBC)
    Washington, DC, United States 2003
    American Association for Cancer Research, Annual Meeting
  • Antitumor activity of combinations of tamoxifen and Herceptin in BT-474 human breast cancer cells
    Washington, DC, United States 2003
    American Association for Cancer Research, Annual Meeting
  • Adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high risk breast cancer (BC)
    Chicago, IL, United States 2003
    American Society of Clinical Oncology, Annual Meeting
  • Activated (phosphorylated) HER-2/neu in breast cancer
    New York, NY, United States 2002
    The Society for Applied Immunohistochemistry Symposium
  • Use of Herceptin in breast cancer
    Jasper, AB, Canada 2002
    The North Alberta Breast Cancer Program Symposium
  • Management Options in Metastatic Breast Cancer
    New York, NY, United States 2002
    Centralized Tumor Conference/Grand Rounds
  • Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
    Ottawa, ON, Canada 2002
    Ottawa Regional Cancer Centre Grand Rounds
  • Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
    Kingston, ON, Canada 2002
    Kingston Regional Cancer Centre Lecture
  • Activation state of HER-2/neu: Clinical implications
    Boston, MA, United States 2001
    Dana-Farber Cancer Institute Breast Cancer Conference
  • Activation state of HER-2/neu: Clinical implications
    Toronto, ON, Canada 2001
    Greater Toronto Area Breast Cancer and Lymphoma Update
  • Activation state of HER-2/neu: Clinical implications
    Calgary, AB, Canada 2000
    Tom Baker Cancer Centre Grand Rounds
  • Activation state of HER-2/neu: Clinical implications
    Scottsdale, AZ, United States 2000
    The Canadian Oncology Leaders Conference
  • The prognostic value of molecular marker expression in oral and oropharyngeal squamous cell carcinoma
    San Francisco, CA, United States 2000
    The 5th International Conference on Head and Neck Cancer
  • Signaling status of HER-2/neu as a prognostic factor in breast cancer
    Atlanta, GA, United States 2000
    Annual Meeting, The Department of Defense Breast Cancer Research Program Meeting
  • Signaling status of HER-2/neu as a prognostic factor in breast cancer
    Atlanta, GA, United States 2000
    The Department of Defense Breast Cancer Research Program, Annual Meeting
  • Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
    Meriden, CT, United States 2000
    Midstate Medical Center, John M. McIntyre Symposium
  • Synergistic interactions between tamoxifen and HerceptinTM
    San Francisco, CA, United States 2000
    American Association for Cancer Research, Annual Meeting
  • Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neu
    Norwalk, CT, United States 2000
    Norwalk Hospital Cancer Center, Breast Cancer Conference
  • ErbB-2, activated ErbB-2 and EGFR immunoexpression in breast cancers
    San Antonio, TX, United States 1999
    San Antonio Breast Cancer Symposium
  • Activation state of HER-2/neu: Clinical implications
    New Orleans, LA, United States 1999
    American Society of Clinical Pathologists Meeting
  • Breast cancer update
    Glastonbury, CT, United States 1999
    The Claire C. Courtney Breast Cancer Foundation
  • Activated erbB-2 immunodetection using PN2A: Biologic and prognostic associations
    San Antonio, TX, United States 1998
    San Antonio Breast Cancer Symposium
  • How Breast Cancer Arises
    New Haven, CT, United States 1998
    Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium
  • Pattern of tyrosine phosphorylation of Neu (HER-2/erbB-2) provides a model for breast tumorigenesis in transgenic mice
    New Orleans, LA, United States 1998
    American Association for Cancer Research, Annual Meeting
  • Activation of HER-2/neu in breast cancer
    Washington, DC, United States 1997
    The Department of Defense Breast Cancer Research Program, Annual Meeting
  • Activation state of HER-2/neu: Clinical implications
    Davis, CA, United States 1997
    University of California, Davis, Oncology Grand Rounds
  • Functional assay for HER-2/neu in invasive breast carcinoma demonstrates active signaling in a minority of cases with HER-2/neu overexpression. Clinicopathologic correlations.
    Washington, DC, United States 1996
    American Association for Cancer Research, Annual Meeting
  • Activation State Specific Anti-p185neu/erbB2 Monoclonal Antibody Detects the Phosphorylated Receptor in Breast Tumors
    Toronto, ON, Canada 1995
    American Association for Cancer Research, Annual Meeting
  • Myeloid Differentiation Associated Protein Tyrosine Kinase Activity in a Murine Monomyelocytic Leukemia Cell Line
    San Francisco, CA, United States 1989
    American Association for Cancer Research, Annual Meeting
  • Measurement of Cytotoxicity and DNA Crosslinks Induced by Mitomycin C (MC) and MC-analogs in Aerobic and Hypoxic EMT6 Cells
    New Orleans, LA, United States 1988
    American Association for Cancer Research, Annual Meeting
  • In Vivo Effects of Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rGM-CSF) in Cyclophosphamide (CTX) Treated Mice
    New Orleans, LA, United States 1988
    American Association for Cancer Research, Annual Meeting

Honors & Recognition

AwardAwarding OrganizationDate
Alvan R. Feinstein AwardYale School of Medicine2019
Swebilius Translational Cancer Research AwardYale University2006
Women's Health Investigator AwardEthel F. Donaghue Women's Health Investigator Program at Yale2005
American Cancer Society Research Scholar GrantAmerican Cancer Society2002
Angel of Hope AwardAmerican Cancer Society2002
Career Development AwardUS Army Medical Research & Materiel Command Department of Defense1997
Hoffman-La Roche Travel AwardAmerican Association for Cancer Research1996
Postdoctoral Fellowship AwardUS Army Medical Research & Development Command Department of Defense1994

Professional Service

OrganizationRoleDate
Yale Department of Medicine, Search committee for Chief of GeriatricsSearch committee for Chief of Geriatrics2019 - 2020
Yale Medical Oncology, Retreat Planning CommitteePlanning committee for section retreat2019 - 2020
Search Committee for Geriatrics Section Chief, YSMSearch Committee for Geriatrics Section Chief2019 - Present
Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2018Presenter for meeting review; Hosted by Yale, attended by regional audience2018
JCO Precision OncologyReviewer2018 - Present
Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2017Meeting review; Hosted by Yale, attended by regional audience2017
Education Policy and Curriculum Committee, YSMAs a YSM curriculum director, I serve on the EPCC which oversees all of medical education2016 - Present
Integrated Courses Review Committee, YSMChair2015 - Present
Course Directors MeetingsAs Co-Director of the Pre-Clerkship Curriculum for YSM, I co-chair this monthly meeting of all YSM course and thread leaders2015 - Present
Genes & Development Master Course, YSMCo-Leader of one of eight "Master Courses" that constitute the YSM pre-clerkship curriculum2015 - Present
LCME Academic Environment Subcommittee, YSMCommittee to address academic environment in preparation for LCME school review2014 - 2015
Yale ASCO Review 2014: Highlights of the Annual MeetingMeeting review; Hosted by Yale, attended by regional audience2014
Yale Cancer Center Evening Oncology Series: Breast Cancer, “Highlights from the San Antonio Breast Cancer SymposiumPresentation of national meeting highlights; Hosted by Yale, attended by regional audience2014
Pharmacology Thread Leader, YSMCo-Leader of pharmacology curriculum for the YSM in the new curriculum2013 - Present
Yale ASCO Review 2013: Highlights of the Annual MeetingMeeting review; Hosted by Yale, attended by regional audience2013
Connecticut Breast Health Initiative, Inc., “CT Race in the Park”Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation2013
Yale Cancer Center Evening Oncology Series: Breast Cancer, “An Update from the San Antonio Breast Cancer Symposium”Review of national meeting; Hosted by Yale, attended by regional audience2013
Curriculum Rebuild Advisory Group, YSMCommittee charged with creating a new curriculum for YSM; my design proposal was instrumental in the new YMS curriculum2013 - 2014
Yale Cancer Center Breast Cancer Retreat, “Breast Oncology Clinical Trial Portfolio”Presentation on Yale breast cancer clinical trials to regional oncologists2012
Clinical Reasoning Goals Committee, YSMCommittee charged with drafting guidelines for the teaching of clinical reasoning in the YSM new curriculum2012 - 2014
Clerkship Component Committee, YSMCommittee charged with drafting structure of YSM clerkships in the new curriculum2012 - 2014
EPIC Steering Committee for Smilow Cancer HospitalCommittee to make recommendations about new electronic medical record system specific for Smilow Cancer Hospital2012 - 2013
Master Course Committee, YSMCommittee charged with structuring the new courses for the new curriculum for YSM; my design proposal was instrumental in the new YMS curriculum2012 - 2013
Yale ASCO Review 2012: Highlights of the Annual MeetingMeeting review; Hosted by Yale, attended by regional audience2012
Connecticut Breast Health Initiative, Inc., “CT Race in the Park”Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation2012
Yale Medical Student Thesis Awards CommitteeMember2012 - Present
Connecticut Breast Health Initiative, Inc., Program for DonorsInvited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation2012
Women’s Health Research at YaleGrant reviewer2012
Yale Cancer Center Evening Oncology Series: Breast Cancer, “New Agents for the Treatment of Breast Cancer”Lecture in Yale Cancer Center seminar series for practicing oncologists; Hosted by Yale, attended by regional audience2012
Connecticut Breast Health Initiative, Inc., “CT Race in the Park”Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation2011
Connecticut Breast Health Initiative, Inc., Program for DonorsInvited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation2011
Yale Cancer Center Clinical Research Program in Breast CancerServed as Interim Program Leader for the Yale Cancer Center Breast Cancer Program2011 - 2012
Yale Cancer Center Oncology Series: Breast Cancer, “Case Study: Caring for Locally Advanced Disease”Yale Cancer Center seminar series for practicing oncologists; Hosted by Yale, attended by regional audience2010
Breast Center Smilow Cancer Hospital Steering CommitteeCommittee to govern policy for Smilow Cancer Hospital Breast Center2010 - 2017
Breast Cancer Research and TreatmentReviewer2010 - Present
High school student laboratory research mentorMentored high school student to conduct summer research project in my lab2010
WNPR Health Forum Radio Program “Yale Cancer Center Answers”Guest interview on Yale radio program2010
Connecticut Breast Health Initiative, Inc., “CT Race in the Park”Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation2010
Connecticut Breast Health Initiative, Inc., Program for DonorsInvited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation2010
“Hope, Not Fear” Fourth Annual Breast Cancer Community Forum, “What Is Breast Cancer”Invited speaker at community breast cancer forum2009
Connecticut Breast Health Initiative, Inc., Howard H. Belkin Memorial Golf TournamentInvited guest researcher/speaker at fundraising golf tournament for a breast cancer research grant awarding foundation2009
Connecticut Breast Health Initiative, Inc., “CT Race in the Park”Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation2009
WNPR Health Forum Radio Program “Yale Cancer Center Answers”Guest interview on Yale radio program2009
Current Pharmacogenomics and Personalized MedicineReviewer2009 - Present
Connecticut Breast Health Initiative, Inc., Program for DonorsInvited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation2009
Women’s Health Research at Yale, Community Council, “Innovations in Cancer Treatment: Why a Breast Cancer Doctor is Studying Lung Cancer”Invited lecture to a women's health research council; Hosted by Yale, attended by regional audience2008
“Medical Files” Saudi Arabian Channel 2 Television Program, Riyadh, Kingdom of Saudi ArabiaInvited interviewed guest on television program2008
“Hope, Not Fear” Third Annual Breast Cancer Community Forum, “What Is Breast Cancer”Invited speaker at community breast cancer forum2008
Pharmacology Curriculum Director, YSMLeadership of all teaching of pharmacology to Yale medical students2008 - 2016
Strategic Planning Committee, YSMAs a curriculum director for YSM, served on this strategic planning committee who was charged with creating a new vision for medical curriculum at YSM going forward; lead to an entirely reformed, rebuilt curriculum2008 - 2011
Donaghue Women’s Health Grants at YaleGrant reviewer2008
WNPR Health Forum Radio Program “Yale Cancer Center Answers”Guest interview on Yale radio program2007
Molecular Cancer ResearchReviewer2007 - Present
American Cancer Society, Laboratory Tours and Lecture for DonorsLecture and tour of my lab for major donors to American Cancer Society2007
YSM Curriculum Director, Director of Modules (Pathophysiology)Served as YSM curriculum director overseeing all clinical Modules in the pre-clerkship curriculum (pathophysiology courses)2007 - 2016
Curriculum Committee, YSMAs a curriculum director, serve on this committee that oversees YSM curriculum2007 - 2016
Module Review Committee, YSMAs Director of Modules (Pathophysiology) for the YSM curriculum, I chaired this committee that critically reviewed all Modules2007 - 2015
Module Directors MeetingsAs Director of Modules (Pathophysiology) for YSM, I chaired this monthly meeting of all Module Directors2007 - 2015
Education Policy Committee, YSMAs a curriculum director for YSM, served on this committee that oversees all YSM education policy2007 - 2014
“21st Century Conversations” CTV Television Program, New Haven CTInvited interviewed guest on television program2007
American Cancer Society, Laboratory Tours and Lecture for DonorsLecture and tour of my lab for major donors to American Cancer Society2006
Cancer ResearchReviewer2006 - Present
Susan G. Komen Breast Cancer Foundation, “Breast Cancer: Survive and Conquer” SymposiumInvited lecturer for breast cancer foundation2006
American Cancer Society, Lecture, Fundraising Event for new building in CTLecture at American Cancer Society fundraising event2006
Healthline WTIC Radio Program, Farmington CTGuest interview on Yale radio program2006
Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium, Keynote AddressKeynote speaker for Y-ME national breast cancer organization symposium2005
American Cancer Society, Colleges Against Cancer, Breast Cancer AwarenessServed as panelist for American Cancer Society breast cancer awareness event2005
American Cancer Society, Laboratory Tours and Lecture for DonorsLecture and tour of my lab for major donors to American Cancer Society2005
American Cancer Society, “Broadway on Beachside” Fundraising EventInvited grant recipient at American Cancer Society fundraising event2005
Breast Cancer Tumor Board, Yale Cancer CenterChair of this meeting where all new or challenging cases of breast cancer are presented in a multidisciplinary format for treatment recommendations and planning2005 - Present
Breast Cancer Tumor Board, Yale Cancer CenterChair of this meeting where all new or challenging cases of breast cancer are presented in a multidisciplinary format for treatment recommendations and planning2005 - Present
American Cancer Society, Laboratory Tours and Lecture for DonorsLecture and tour of my lab for major donors to American Cancer Society2004
American Cancer Society, “Table of Ten” Fundraising DinnerInvited grant recipient at American Cancer Society fundraising event2004 - 2010
Swebilius Translational Cancer Research Awards at YaleGrant reviewer2004
Yale-New Haven Breast Center CME Symposium: Update on Breast Disease 2004 – Multidisciplinary Breast Tumor BoardYale breast cancer CME event; Hosted by Yale, attending by regional audience2003
American Cancer Society, Laboratory Tours and Lecture for DonorsLecture and tour of my lab for major donors to American Cancer Society2003
Oncology ResearchReviewer2003 - Present
American Cancer Society, “Broadway on Beachside” Fundraising EventInvited grant recipient at American Cancer Society fundraising event2003
British Journal of CancerReviewer2003 - Present
Clinical Cancer ResearchReviewer2003 - Present
Connecticut State Breast Cancer Research AwardsGrant reviewer2003
Brown-Cox AwardsGrant reviewer2003
American Cancer Society, Laboratory Tours and Lecture for DonorsLecture and tour of my lab for major donors to American Cancer Society2002
American Cancer Society, “Broadway on Beachside” Fundraising EventInvited grant recipient at American Cancer Society fundraising event2002
The FASEB JournalReviewer2002 - Present
Department of Defense, Breast Cancer Research Program “Pathobiology 1”Study section grant reviewer, "Pathobiology 1"2001
Breast Cancer Research Program, Yale Cancer CenterServed as Co-Director of the Yale Cancer Center's Breast Cancer Research Program2001 - 2008
Journal of Clinical OncologyReviewer2001 - Present
Yale Pathology Series on Contemporary Issues in Diagnostic Assessment - Detection, Treatment and Prevention of Breast Cancer: A Molecular PerspectiveLecture in Yale pathology seminar series; Hosted by Yale, attended by regional audience1999
Oncology Module Course Director, YSMDirector of oncology course for YSM medical students1999 - 2016
Protocol Review Committee, Yale Cancer CenterCommittee that critically reviews and is required to approve all clinical trials in the Yale Cancer Center1999 - 2014
The Claire C. Courtney Breast Cancer FoundationInvited lecture for a breast cancer foundation1999
Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium, Keynote AddressKeynote speaker for Y-ME national breast cancer organization symposium1998
Pharmacology course YSM, Seminar conference leaderLead cancer therapeutics small group seminar selective in YSM pharmacology course1998 - 2016
Medical Oncology New Patient Intake Conference, Yale Cancer CenterDiscussant/Conference Leader for this series in which medical oncology fellows present new patients they have seen for educational discussion1998 - 2007
Medical Oncology Fellowship Seminar SeriesLecturer in Yale Medical Oncology Fellowship Seminar Series1998 - Present
Yale Breast Cancer Research Program Developmental Funds AwardsGrant reviewer1998
Yale Affiliated Hospitals and Faculty Resource ProgramLecturer for the Yale Affiliated Hospitals and Faculty Resource Program1997 - Present
Yale Cancer CenterMember of Yale Cancer Center1997 - Present
Biochemical PharmacologyReviewer1997 - Present
The Journal of Clinical InvestigationReviewer1997 - Present
Journal of Clinical GastroenterologyReviewer1997 - Present
Laboratory InvestigationReviewer1997 - Present
Molecular DiagnosisReviewer1997 - Present

Departments & Organizations